文献速递疼痛医学

CXCL12/CXCR4信号参与阿片耐受发病机制:一项转化研究

CXCL12/CXCR4 Signaling Contributes to the Pathogenesis of Opioid Tolerance: A Translational Study.
PubMed 文献 · Anesth Analg · 2017-01-01

该转化研究比较阿片耐受患者与未使用阿片者脑脊液CXCL12水平,并在大鼠中采用腹腔注射与鞘内输注吗啡两种临床相关范式,发现CXCL12/CXCR4信号参与阿片耐受发病机制,干预该通路具有治疗潜力。

要点

  • 阿片耐受患者脑脊液CXCL12较未使用阿片者显著升高。
  • 大鼠鞘内吗啡输注后腰段脊髓背角CXCL12 mRNA显著上调。
  • 鞘内CXCL12加速耐受,中和抗体或AMD3100可减轻或延缓耐受。

核心结论

  • CXCL12/CXCR4通路参与阿片耐受的发病机制,干预该信号具有治疗潜力。

研究设计与样本

  • 转化研究:比较阿片耐受患者与未使用阿片者脑脊液CXCL12水平。
  • 大鼠采用每日腹腔注射吗啡与持续鞘内输注吗啡两种临床相关给药范式。
  • 以甩尾反应计算最大可能效应百分比(%MPE)评估急性镇痛与耐受。
  • 经鞘内给予外源性CXCL12、CXCL12中和抗体及受体拮抗剂AMD3100进行干预。

主要发现

  • 阿片耐受患者脑脊液CXCL12为892 ± 34 pg/mL(n = 27),未使用阿片对照为755 ± 33 pg/mL(n = 10),P = .03。
  • 鞘内吗啡输注2天和5天后,大鼠腰段脊髓背角CXCL12 mRNA分别上调3.2 ± 0.7倍(P = .016)和3.4 ± 0.3倍(P = .003)。
  • 每日腹腔注射吗啡实验中,首次注射前鞘内输注CXCL12 24小时未降低第1天镇痛效能,但第2天后加速耐受(%MPE 49.5% vs 88.1%,P = .0003)。
  • 鞘内吗啡共输注实验中,CXCL12加速耐受(第1天%MPE 9.4% vs 43.4%,P < .0001)。
  • CXCL12中和抗体减轻耐受(第1天72.5% vs 43.4%,P < .0001;第2天47.6% vs 17.5%,P < .0001);AMD3100持续保留吗啡镇痛效应(第5天27.9% ± 4.1% vs 0.9% ± 1.6%,P = .03)。

临床怎么用

  • CXCL12/CXCR4信号可作为阿片耐受的潜在治疗靶点。
  • 受体拮抗剂AMD3100在动物实验中可持续保留吗啡镇痛效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term opioid therapy for chronic pain may lead to analgesic tolerance, especially when administered intrathecally, thus preventing adequate pain relief. Discovering drug targets to treat opioid tolerance using a mechanism-based approach targeting opioid-induced neuroinflammation provides new therapeutic opportunities. In this study, we provide translational evidence that CXCL12/CXCR4 signaling contributes to the pathogenesis of opioid tolerance. METHODS: The CXCL12 levels in the cerebrospinal fluid of opioid-tolerant patients were compared with those of opioid-naive subjects. For further investigation, a rodent translational study was designed using 2 clinically relevant opioid delivery paradigms: daily intraperitoneal morphine injections and continuous intrathecal morphine infusion. We measured rats' tail flick responses and calculated the percentage of maximum possible effects (%MPE) to demonstrate opioid acute antinociception and the development of analgesic tolerance. The effects of exogenous CXCL12, CXCL12 neutralizing antibody, and receptor antagonist AMD3100 were investigated by intrathecal administration. Data were presented as mean ± SEM. RESULTS: CXCL12 was significantly upregulated in the cerebrospinal fluid of opioid-tolerant patients for 892 ± 34 pg/mL (n = 27) versus 755 ± 33 pg/mL (n = 10) in naive control subjects (P = .03). Furthermore, after 2 and 5 days of intrathecal morphine infusion, rat lumbar spinal cord dorsal horn CXCL12 messenger RNA levels were significantly upregulated by 3.2 ± 0.7 (P = .016) and 3.4 ± 0.3 (P = .003) fold, respectively. Results from the daily intraperitoneal morphine injection experiments revealed that administering an intrathecal infusion of CXCL12 for 24 hours before the first morphine injection did not decrease antinociception efficacy on day 1 but accelerated tolerance after day 2 (%MPE 49.5% vs 88.1%, P = .0003). In the intrathecal morphine coinfusion experiments, CXCL12 accelerated tolerance development (%MPE 9.4% vs 43.4% on day 1, P < .0001), whereas coadministration with CXCL12 neutralizing antibody attenuated tolerance (72.5% vs 43.4% on day 1, P < .0001; 47.6% vs 17.5% on day 2, P < .0001). Coadministration of receptor antagonist AMD 3100 can persistently preserve morphine analgesic effects throughout the study period (27.9% ± 4.1% vs 0.9% ± 1.6% on day 5, P = .03). CONCLUSIONS: The CXCL12/CXCR4 pathway contributes to the pathogenesis of opioid tolerance. Our study indicates that intervening with CXCL12/CXCR4 signaling has therapeutic potential for opioid tolerance.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Lin CP, Kang KH, Tu HJ, et al. CXCL12/CXCR4 Signaling Contributes to the Pathogenesis of Opioid Tolerance: A Translational Study. Anesth Analg. 2017. PMID: 28212183. doi:10.1213/ANE.0000000000001480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。